Harnessing naturally occurring mutations for T-cell therapy: a potential new avenue to enhance treatment efficacy
Signal Transduct Target Ther
.
2024 Apr 30;9(1):117.
doi: 10.1038/s41392-024-01835-y.
Authors
Michael Hiltensperger
1
,
Jürgen Ruland
2
3
4
5
,
Kilian Schober
6
7
Affiliations
1
Mikrobiologisches Institut-Klinische Mikrobiologie, Immunologie und Hygiene, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany. michael.hiltensperger@uk-erlangen.de.
2
Institute of Clinical Chemistry and Pathobiochemistry, School of Medicine, Technical University of Munich, Munich, Germany.
3
TranslaTUM, Center for Translational Cancer Research, Technical University of Munich, Munich, Germany.
4
German Cancer Consortium (DKTK), Heidelberg, Germany.
5
German Center for Infection Research (DZIF), partner site Munich, Munich, Germany.
6
Mikrobiologisches Institut-Klinische Mikrobiologie, Immunologie und Hygiene, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
7
FAU Profile Center Immunomedicine, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
PMID:
38688914
PMCID:
PMC11061186
DOI:
10.1038/s41392-024-01835-y
No abstract available
Publication types
Research Support, Non-U.S. Gov't
Letter
MeSH terms
Cell- and Tissue-Based Therapy
Humans
Mutation*
T-Lymphocytes* / immunology